8-K filing — IONIS PHARMACEUTICALS INC (IONS)
Filed: 2026-09-04 AccNo: 0001140361-26-035802 Size: 181 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Ionis Pharmaceuticals Exec Says Zanvastro Will Be Available At List Price Of $285K Per Dose
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Ionis Pharmaceuticals shares are trading lower amid sympathy with Novartis after the company announced the pelacarsen phase III Lp(a)HORIZON trial did not meet its primary endpoint. Novartis obtained global rights to develop, manufacture and commercialize pelacarsen under a license and collaboration agreement with the company.
Novartis’ Pelacarsen Phase III Lp(a)HORIZON Trial Fails Primary Cardiovascular Endpoint; Lowered Lp(a) Levels But Did Not Reduce CV Events
Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of
Needham Reiterates Buy on Ionis Pharmaceuticals, Maintains $86 Price Target